Cargando…

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects

BACKGROUND AND OBJECTIVES: Second-generation antipsychotics (SGAs) for schizophrenia show different risk profiles, whose evidence has been evaluated through comparative reviews on randomized controlled trials (RCTs) and observational studies. METHODS: We performed a systematic review and meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rognoni, Carla, Bertolani, Arianna, Jommi, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004512/ https://www.ncbi.nlm.nih.gov/pubmed/33686614 http://dx.doi.org/10.1007/s40261-021-01000-1

Ejemplares similares

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
por: Hirsch, Lauren, et al.
Publicado: (2018)

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

Il costo a carico dei pazienti del percorso per eleggibilità ai farmaci PCSK9 e follow-up di un anno: i risultati dello Studio PRIOR
por: Bertolani, Arianna, et al.
Publicado: (2022)

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
por: Scigliano, Giulio, et al.
Publicado: (2013)

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis
por: Belvederi Murri, Martino, et al.
Publicado: (2015)

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia
por: Sampogna, Gaia, et al.
Publicado: (2023)

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?
por: Venkatasubramanian, Ganesan, et al.
Publicado: (2013)

Onset of Action of Selected Second-Generation Antipsychotics (Pines)–A Systematic Review and Meta-Analyses
por: Meyer, Rikke, et al.
Publicado: (2022)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Il futuro dei Fondi per Farmaci Innovativi: risultati di uno studio basato su Delphi panel
por: Jommi, Claudio, et al.
Publicado: (2021)

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
por: Kearns, Benjamin, et al.
Publicado: (2021)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang, Xinyu, et al.
Publicado: (2019)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari, Sulaiman, et al.
Publicado: (2015)

F56. IMPACT OF SIDE EFFECTS DUE TO SECOND-GENERATION ANTIPSYCHOTICS ON THE FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA: AN OBSERVATIONAL, PATIENT CENTERED, WEB SURVEY
por: Tandon, Rajiv, et al.
Publicado: (2018)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis
por: Zhang, Yangyu, et al.
Publicado: (2017)

T220. IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC SIDE EFFECTS ON FUNCTIONING FROM A SCHIZOPHRENIA PATIENT PERSPECTIVE: GLOBAL PATIENT CENTERED SURVEY INCLUDING PATIENTS FROM ITALY
por: Weiss, Catherine, et al.
Publicado: (2020)

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia
por: Freyberg, Zachary, et al.
Publicado: (2017)

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients
por: Misiak, Błażej, et al.
Publicado: (2014)

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
por: Mahmoud, Ahmed, et al.
Publicado: (2011)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
por: Adkins, Daniel E., et al.
Publicado: (2010)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

Dysphagia with second-generation antipsychotics: A case report and review of the literature
por: Crouse, Ericka L., et al.
Publicado: (2018)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis
por: Zheng, Wei, et al.
Publicado: (2019)

Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics
por: Rice, Jessie, et al.
Publicado: (2020)

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
por: Grajales, Diana, et al.
Publicado: (2019)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia
por: Jiang, Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ks0kjbu56aneidf1r3j1j9t2lc